• Mission

    Spring Bank is devoted to pioneering its revolutionary SMNH chemistry platform to discover and develop a new generation of medicines to improve the lives of patients worldwide.
  • Our Technology

    Our proprietary small molecule nucleic acid hybrids (SMNH) chemistry platform produces a class of compounds designed to selectively target and modulate the activity of specific proteins implicated in various disease states with the favorable drug-like qualities of traditional small molecules.
  • Clinical Trials

    Get the latest information about our ongoing clinical trials.
    Details
  • Latest News

      • NOVEMBER 15, 2011

      Spring Bank Pharmaceuticals Receives Allowance for US Patent

      Spring Bank Pharmaceuticals Receives Allowance for US Patent entitled Nucleotide and Oligonucleotide Prodrugs Milford, MA, November 15, 2011 – Spring Bank Pharmaceuticals, Inc., announces that the United States Patent and Trademark Office has allowed the U.S. patent 11/637,520 (“the patent”) titled “Nucleotide and Oligonucleotide Prodrugs”, co-inventors Iyer and Padmanabhan. This patent relates to the design,

      Read more